HC Wainwright Issues Optimistic Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of ArriVent BioPharma in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.78) per share for the quarter, up from their previous estimate of ($0.81). HC Wainwright has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS and FY2025 earnings at ($3.41) EPS.

ArriVent BioPharma Stock Up 0.2 %

AVBP stock opened at $27.30 on Friday. The firm’s fifty day simple moving average is $26.99 and its 200-day simple moving average is $26.03. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $36.37.

Institutional Investors Weigh In On ArriVent BioPharma

Several hedge funds have recently added to or reduced their stakes in AVBP. Rhumbline Advisers lifted its holdings in shares of ArriVent BioPharma by 30.1% in the 2nd quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock valued at $236,000 after buying an additional 2,942 shares during the period. Novo Holdings A S raised its position in ArriVent BioPharma by 39.3% during the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $27,825,000 after acquiring an additional 422,860 shares in the last quarter. SG Americas Securities LLC acquired a new position in ArriVent BioPharma in the third quarter valued at approximately $280,000. Charles Schwab Investment Management Inc. boosted its position in ArriVent BioPharma by 153.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock worth $4,756,000 after purchasing an additional 122,641 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of ArriVent BioPharma during the 3rd quarter worth approximately $240,000. 9.48% of the stock is owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.